Savan is the Founder and CEO of BioTrillion, a health technology company developing an AI-based platform called BioEngine4D to generate novel “digital biomarkers” in Neurology with applications in: data-driven drug development and digitally detecting developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a Healthcare Investment Banker at Citigroup, Deutsche Bank. From Analyst through Managing Director, he led ~40 M&A, IPO, and financing deals, totaling $35+ billion in value, and experienced many invaluable business and scientific lessons from his work with clients across the spectrum of drug, diagnostic, and device technologies. Some of these companies included Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others. While a Vice President at Deutsche Bank, Savan was selected to lead the firm's build-out of its Healthcare business into Asia, leading to IPO's of the two largest healthcare companies in China: Shanghai Pharma and Fosun Pharma. Savan began his career as a Bioengineer at Life Technologies.
Savan graduated with a M.S.E. in Bioengineering from the University of Pennsylvania and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley.
After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life gave Savan a new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage 4 cancer. This compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to him returning to his Bioengineering roots and founding BioTrillion.
Pranav began his career as an investment banker at FBR & Co., where he focused on the financial institutions and real estate verticals. After several years in investment banking, he became a business consulant to technology clients.
Pranav holds degrees in the Liberal Arts from the University of Pennsylvania and UT Austin.
Matthijs Hollemans, Senior iOS Computer Vision and Machine Learning Developer, is building the LIFEdata feature extraction technology behind BioEngine4D.
Matthijs is a world-leading machine learning and computer vision software engineering expert, specialized in deep learning model development for iOS. He is the author of “Core ML Survival Guide,” “Machine Learning by Tutorials,” and "iOS Apprentice.” Over the course of his 20-year career, Matthijs has worked on a variety of software development, iOS, and machine learning technologies in diverse industries.
Samir is a Biology major at the University of Oxford. He is an active member of the biotech and life sciences community in the UK’s Golden Triangle of Cambridge, London, and Oxford and has been devoting his interests and efforts to advancing biological innovations with digital technology. Recognising San Francisco as a global hub of scientific and entrepreneurial activity, Samir took a year out of his Oxford degree to intern at BioTrillion.
Shira's interests are focused where technology and life sciences intersect. She is passionate about the power that Bio and Technology hold, and the transformative opportunities it creates to solve problems that previously seemed impossible to overcome. Shira focused her last internship in Computer Vision and is earning her degree in Biomedical Computing at Queen’s University, a leading academic institution in Canada. Shira interned at BioTrillion in the Summer of 2019 and continues to intern with the Company while completing her Biomedical Computing degree.
Dr. Kirk was at NVIDIA for over 20 years, and served in many roles, including Chief Scientist, Vice President of Architecture, and most recently, Fellow. Dr. Kirk received the Distinguished Alumni award from Caltech in 2009. He was elected in 2006 to the National Academy of Engineering (NAE) for his role in bringing high-performance graphics to personal computers. In 2002, he received the SIGGRAPH Computer Graphics Achievement Award for his role in bringing high-performance computer graphics systems to the mass market. Dr. Kirk is the inventor of more than 60 patents and patent applications relating to graphics design and has published more than 50 articles on graphics technology. He also co-authored the popular textbook “Programming Massively Parallel Processors.”
Dr. Kirk holds B.S. and M.S. degrees from MIT and M.S. and Ph.D. degrees in Computer Science from Caltech, with a minor in Computation and Neural Systems.
Dr. Kumar is a Lillian & Morrie Moss Chair of Excellence Professor in Computer Science at the University of Memphis. His research focuses on using mobile sensors for self-monitoring of health, wellness, and performance. Dr. Kumar's research group has developed computational models to infer human health and behaviors such as stress, conversation, smoking, craving, brushing, flossing, and drug use from wearable sensor data. He leads several large federally-funded multidisciplinary projects in mobile sensor big data funded by NIH, NSF, and IARPA (worth over $40 million). Dr. Kumar is currently Center Director and Lead PI of the NIH Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K) that involve investigators in computing, engineering, behavioral science, and medicine from 17 universities. In 2010, he was named "Sensor Guru" by the Popular Science magazine as part of their profiling of America's Ten Brilliant Young scientists and is a frequent keynote speaker or presenter at universities, medical schools, federal agencies including at the White House, international conferences, and national meetings of experts.
Dr. Kumar holds a PhD in Computer Science from Ohio State and BS in Computer Science from the prestigious Indian Institute of Technology (IIT).
Dr. Su is a seasoned Bioengineer with over 20 years of experience in the medical device and pharmaceutical industry. His expertise includes combinational device and pharmaceutical formulation. Dr. Su spent the majority of his professional career at Biosensors International, where he rose through the ranks to Director of R&D, until the Company’s acquisition. He has extensive experience in taking conceptual R&D ideas to human clinical trial and finally to commercialization. He is inventor/co-inventor of 32 issued worldwide patents and 25 pending patent applications.
Dr. Su holds a Bachelor’s degree in Chemical Engineering, and Masters and PhD degrees in Biomedical Engineering.
Dr. Fontanella brings tremendous clinical experience from his years at the prestigious Memorial Sloan Kettering Cancer Center, as both a data science researcher and as Chief Resident in Medical Physics. Throughout his 10+ years of experience in a healthcare environment, he has developed a passion for developing quantitative methods for improving cancer patients’ treatment outcomes. His personal experiences of seeing close family members bravely battling deadly diseases has sparked a deep drive within him to apply his knowledge and experience towards the improvement of healthcare in the US through advanced machine learning techniques.
Dr. Fontanella graduated with a PhD in Biomedical Engineering from Duke University while studying under the mentorship of Mark Dewhirst, a renowned leader in the field of tumor microcirculation and targeted drug delivery. His thesis work involved in vivo observation of vascular radiation-response in tumors using optical techniques. He also holds a Masters degree in Electrical and Computer Engineering, with a focus in Optics, Photonics, and Image Processing.
Sunil brings over 20 years of biotech management and R&D experience, with significant emphasis on dealmaking to enable value creation from innovation. Most recently, he was EVP & CFO of OncoMed Pharmaceuticals (NASDAQ: OMED), a cancer therapeutics company. He is also currently a member of the Board of Directors of Ligand Pharmaceuticals (NASDAQ: LGND). Sunil has also held roles in finance, business development, and marketing, including positions with OncoMed, BiPar, Allos, Connetics, Abgenix, and Gilead. Earlier in his career, he was with McKinsey & Company advising both biotech and high tech companies. Sunil started his career in the lab, including working as an analytical protein chemist with ZymoGenetics. He is passionate about leveraging novel technologies to improve healthcare, with a particular interest in opportunities at the intersection of the revolutions taking place in IT and biotech.
Sunil graduated with a M.S. in Molecular Bioengineering from the University of Washington and a B.S. in Chemistry from the University of California at Berkeley.